Pyoderma gangrenosum
Chapter 12:Diseases of the skin and subcutaneous tissue
ICD-10 L88 is a billable code used to indicate a diagnosis of pyoderma gangrenosum.
Pyoderma gangrenosum (PG) is a rare, inflammatory skin condition characterized by painful ulcers that typically arise on the lower extremities but can occur anywhere on the body. Clinically, PG presents as rapidly progressing, necrotic ulcers with undermined borders and a purulent base. The condition is often associated with systemic diseases, particularly inflammatory bowel diseases, rheumatoid arthritis, and hematological disorders. The pathophysiology of PG is not fully understood but is believed to involve dysregulation of the immune system, leading to neutrophilic infiltration and tissue destruction. Diagnosis is primarily clinical, supported by a thorough patient history and exclusion of other ulcerative conditions. Biopsy may be performed to rule out infections or malignancies, although it may not always be definitive. Disease progression can vary, with some patients experiencing single ulcers while others may have multiple lesions or recurrent episodes. Prompt recognition and management are crucial to prevent complications and improve patient outcomes.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
L88 specifically covers pyoderma gangrenosum, which is characterized by painful ulcers and is often associated with systemic diseases such as inflammatory bowel disease and rheumatoid arthritis.
L88 should be used when the diagnosis is confirmed as pyoderma gangrenosum, particularly when ulcers are present with the characteristic features and associated systemic conditions, differentiating it from other ulcerative skin disorders.
Documentation should include a detailed clinical history, physical examination findings, treatment plans, and any relevant laboratory or biopsy results that support the diagnosis of pyoderma gangrenosum.
